尿酸对复苏后失血性休克大鼠肝损伤及肠通透性的影响
本研究采用复苏后失血性休克大鼠模型,在复苏期间给予重组尿酸酶(拉布立酶)以代谢并降低循环尿酸。结果显示,加用尿酸酶显著降低循环及肝脏尿酸水平,并在24小时和72小时预防失血性休克诱导的肝细胞溶解及肝脏凋亡/炎症介质;72小时生理测试显示,尿酸酶可防止失血性休克诱导的肠高通透性和内毒素血症。体外HT-29细胞暴露于尿酸后检测紧密连接蛋白ZO-1和E-cadherin表达,以评估尿酸对肠通透性的影响。结论认为尿酸是复苏后失血性休克肝肠损伤的重要介质,可作为多发性创伤合并失血性休克患者减轻器官损伤的治疗靶点。
要点
- 复苏期间给予重组尿酸酶(拉布立酶)可显著降低失血性休克大鼠循环及肝脏尿酸水平。
- 尿酸酶在24小时和72小时预防失血性休克诱导的肝细胞溶解及肝脏凋亡/炎症介质升高。
- 尿酸酶可防止失血性休克诱导的肠高通透性和内毒素血症(72小时评估)。
- 体外HT-29细胞暴露于尿酸后检测ZO-1和E-cadherin表达,以评估尿酸对肠通透性的影响。
- 结论:尿酸是复苏后失血性休克肝肠损伤的重要介质,可作为多发性创伤合并失血性休克患者的治疗靶点。
适用人群与场景
- 复苏后失血性休克大鼠模型(小鼠模型)。
- 体外HT-29细胞用于评估尿酸对肠通透性的影响。
- 原文未提及急诊/ICU/院前具体场景及病情阶段的纳入/排除标准。
诊断标准与关键阈值
- 原文未提及
处置流程与药物剂量
- 在复苏期间给予重组尿酸酶(拉布立酶;Sanofi-Aventis, Canada Inc, Laval, Canada)以代谢并降低循环尿酸;原文未提及具体剂量、给药途径、频次或疗程。
- 在失血性休克后24小时和72小时进行生化分析(肝酶、肝脏凋亡及炎症标志物)。
- 在失血性休克后72小时进行肠通透性生理测试及血浆内毒素(肠道细菌产物易位)测量。
- 体外将HT-29细胞暴露于尿酸,检测细胞间黏附蛋白(ZO-1、E-cadherin)表达以评估尿酸对肠通透性的影响。
红旗征与不能漏的情况
- 原文未提及
研究设计与关键结果
- 研究类型:大鼠复苏后失血性休克模型及体外HT-29细胞实验;样本量与中心数原文未提及。
- 干预与对照:复苏期间给予重组尿酸酶(拉布立酶)以代谢并降低循环尿酸;对照原文未详细描述。
- 主要终点结果:加用尿酸酶显著降低循环及肝脏尿酸水平;在24小时和72小时预防失血性休克诱导的肝细胞溶解及肝脏凋亡/炎症介质。
- 关键次要终点:尿酸酶防止失血性休克诱导的肠高通透性和内毒素血症(72小时评估)。
- 体外结果:HT-29细胞暴露于尿酸后检测ZO-1和E-cadherin表达,以评估尿酸对肠通透性的影响;具体结果数值原文未提及。
- 不良事件:原文未提及。
证据类型、等级与局限
- 证据类型:动物实验(大鼠模型)及体外细胞实验。
- 证据等级或推荐强度:原文未提及。
- 局限:动物模型及体外实验,样本量、中心数原文未提及;结果需进一步临床研究验证。
对床旁实践的改变
- 原文提示尿酸可能是复苏后失血性休克肝肠损伤的治疗靶点,但当前证据仅来自大鼠模型及体外细胞实验,尚不能直接改变急诊/ICU床旁实践。
- 适用人群:原文为复苏后失血性休克大鼠模型及HT-29细胞,未提及人类适用人群。
- 不适用人群:原文未提及。
- 常见陷阱:不能将动物实验中的尿酸酶方案(剂量、途径、频次原文未提及)推断为人类推荐;不能将相关性或模型估计数值作为临床决策阈值。
指南或共识出处
- 原文未提及指南或共识;文献来源为J Trauma Acute Care Surg。
以上提炼依据论文摘要(全文未开放获取,或许可不允许翻译转载);全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Multiorgan failure is a consequence of severe ischemia-reperfusion injury after traumatic hemorrhagic shock (HS), a major cause of mortality in trauma patients. Circulating uric acid (UA), released from cell lysis, is known to activate proinflammatory and proapoptotic pathways and has been associated with poor clinical outcomes among critically ill patients. Our group has recently shown a mediator role for UA in kidney and lung injury, but its role in liver and enteric damage after HS remains undefined. Therefore, the objective of this study was to evaluate the role of UA on liver and enteric injury after resuscitated HS.
METHODS: A murine model of resuscitated HS was treated during resuscitation with a recombinant uricase, a urate oxidase enzyme (rasburicase; Sanofi-Aventis, Canada Inc, Laval, Canada), to metabolize and reduce circulating UA. Biochemical analyses (liver enzymes, liver apoptotic, and inflammatory markers) were performed at 24 hours and 72 hours after HS. Physiological testing for enteric permeability and gut bacterial product translocation measurement (plasma endotoxin) were performed 72 hours after HS. In vitro, HT-29 cells were exposed to UA, and the expression of intercellular adhesion proteins (ZO-1, E-cadherin) was measured to evaluate the influence of UA on enteric permeability.
RESULTS: The addition of uricase to resuscitation significantly reduced circulating and liver UA levels after HS. It also prevented HS-induced hepatolysis and liver apoptotic/inflammatory mediators at 24 hours and 72 hours. Hemorrhagic shock-induced enteric hyperpermeability and endotoxemia were prevented with uricase.
CONCLUSIONS: After resuscitated HS, UA is an important mediator in liver and enteric injury. Uric acid represents a therapeutic target to minimize organ damage in polytrauma patients sustaining HS.
参考来源
- Khazoom F, L'Écuyer S, Gilbert K, et al. Impact of uric acid on liver injury and intestinal permeability following resuscitated hemorrhagic shock in rats. J Trauma Acute Care Surg. 2020. PMID: 33231951. doi:10.1097/TA.0000000000002868
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。